Publications by authors named "Qingyuan Zhang"
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.
Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.
Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor, has displayed anti-tumor activity and differentiated safety and tolerability profile in previous ph1/2 clinical trials. The LEONARDA-1, a randomized, double-blind, phase III study, was conducted to evaluate the efficacy and safety of lerociclib in HR+/HER2- locally advanced or metastatic breast cancer patients, who had relapsed or progressed on prior endocrine therapy. A total of 275 patients were randomized at 1:1 ratio to receive lerociclib (137 patients, 150 mg twice daily) or placebo (138 patients) plus fulvestrant.
View Article and Find Full Text PDFBackground: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes.
Methods: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR.
Subcutaneous (SC) rituximab has demonstrated advantages over intravenous (IV) administration; however, insufficient data exist on its use with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Chinese patients with diffuse large B-cell lymphoma (DLBCL). This multicenter, phase II, randomized, controlled study was conducted across China between February 2021 and October 2022. Fifty adult patients with previously untreated CD20-positive DLBCL were randomized to receive one cycle of IV rituximab and seven cycles of SC rituximab (R-CHOP; = 26), or eight cycles of IV rituximab (R-CHOP; = 24), combined with six or eight cycles of CHOP.
View Article and Find Full Text PDFIntroduction: The prognosis of relapsed or refractory mature T- and natural killer (NK)-cell lymphoma remains dismal. Novel agents are urgently needed to improve the outcomes for this population.
Methods: In this phase 2, multicenter, open-label, single-arm study (NCT03776279), the authors report the efficacy and safety of liposomal mitoxantrone (Lipo-MIT) monotherapy in patients with relapsed or refractory mature T- and NK-cell lymphoma.
This study (NCT04728035) aimed to explore the safety and efficacy of liposomal irinotecan (HE072) in patients with metastatic triple-negative breast cancer (mTNBC). This study consisted of two parts. In part 1, the 3 + 3 design was used to investigate three dose levels of HE072 (50, 70 and 90 mg/m).
View Article and Find Full Text PDFSoft robots have developed gradually in the fields of portability, high precision, and low noise level due to their unique advantages of low noise and low energy consumption. This paper proposes an electromagnetically driven elastomer, using gelatin and glycerol (GG) as matrix materials and a mixture of multiwalled carbon nanotubes (MWCNTs) and Ag NWs (MA) as the conductive medium. Inchworm-inspired and spider-inspired soft robots have been developed, demonstrating fast movement speed, flexibility, and loading performance.
View Article and Find Full Text PDFBackground: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα ().
Methods: In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib.
Purpose: This study aims to identify specific sub-types of hope levels in breast cancer (BC) patients and explore the influencing factors.
Methods: Between August and December 2023, 528 BC patients took part in this study. Latent Profile Analysis (LPA) was employed using the Herth Hope Index, Distress Thermometer, Hospital Anxiety and Depression Scale, Social Support Rating Scale, BC survivors' self-efficacy scale and Functional Assessment of Cancer Therapy-Breast to identify clusters of hope levels.
Polatuzumab vedotin plus R-CHP (Pola-R-CHP) is approved as a new standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) based on the POLARIX trial. However, real-world data on its efficacy and safety in unselected patients is lacking. We conducted a retrospective cohort study to evaluate Pola-R-CHP versus R-CHOP outcomes in routine clinical practice in China.
View Article and Find Full Text PDFArticle Synopsis
- * Though generative models like variational autoencoders excel in predicting genetic data distributions, they lack a solid biological basis, while Gene Regulation Networks struggle to integrate genetic and pathway data effectively.
- * A new dual-stream architecture has been proposed that separately processes sequencing and knowledge data before merging, leading to improved accuracy with a 20% reduction in mean squared error.
Article Synopsis
- Grem1 cancer-associated fibroblasts (CAFs) play a vital role in the development of colorectal cancer (CRC), but their origins and functions have been difficult to study due to technical limitations.
- * The research used an optimized gut Swiss-roll technique to create single cryopreserved slides, revealing a significant increase in Grem1 CAFs in tumor tissues compared to normal mucosa at 12 weeks.
- * Lineage tracing showed that most Grem1 CAFs in the tumor core derived from Grem1 intestinal reticular stem cells (iRSCs), indicating their potential as a key target for early CRC therapies, while a smaller subset came from Grem1 intestinal sub-epithelial myofibroblasts
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
Lancet
November 2024
Background: Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a second-line therapy. We investigated the efficacy and safety of glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) versus rituximab (R)-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma.
Methods: The phase 3, randomised, open-label STARGLO trial was done at 62 centres in 13 countries in Asia and Australia, Europe, and North America.
Article Synopsis
- * In a phase 3 trial involving 325 patients, those taking inavolisib had a median progression-free survival of 15.0 months, significantly better than the 7.3 months for the placebo group, indicating better disease management.
- * The treatment with inavolisib showed promising results with a 58.4% objective response rate; however, there were notable side effects, similar between both groups, including high rates of neutropenia
Article Synopsis
- Abemaciclib, the first CDK4/6 inhibitor approved for high-risk hormone-receptor positive early breast cancer, showed positive results based on the phase III monarchE trial, particularly in a Chinese population analysis.
- In this study, 501 Chinese patients with high-risk early breast cancer were randomized to receive either abemaciclib plus endocrine therapy or endocrine therapy alone, with the primary focus on invasive disease-free survival and other key endpoints.
- The findings indicated that the combination of abemaciclib with endocrine therapy significantly improved invasive disease-free survival and distant relapse-free survival rates at the 5-year mark, though it was associated with a higher incidence of certain side effects like neutropenia and leukopenia.
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.
J Immunother Cancer
October 2024
Article Synopsis
- A phase 3 trial compared the effectiveness and safety of zuberitamab combined with CHOP chemotherapy (Hi-CHOP) against rituximab combined with CHOP (R-CHOP) in patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL).
- The trial involved 487 patients, with a primary focus on the objective response rate (ORR) after six treatment cycles, finding that Hi-CHOP achieved a similar ORR to R-CHOP while demonstrating a significantly higher complete response (CR) rate in some analyses.
- Long-term follow-up indicated that Hi-CHOP patients experienced improved duration of response (DOR), progression-free survival (PFS), and overall survival
Rationale And Objective: To investigate the MR characteristics of phlegmonous stage and abscess stage primary spinal epidural abscess.
Materials And Methods: This study retrospectively analyzed the clinical and imaging characteristics of 27 cases of pathologically confirmed primary spinal epidural abscess. Predisposing conditions of all patients were collected.
Article Synopsis
- - The MONARCH plus study found that adding abemaciclib to endocrine therapy significantly improved progression-free survival (PFS) and objective response rate (ORR) in postmenopausal women with HR+/HER2- advanced breast cancer.
- - In the study, cohort A (no prior systemic therapy) showed a median PFS of 28.27 months for abemaciclib users compared to 14.73 months for those on placebo, while cohort B (progression on prior therapy) showed 11.41 months vs. 5.59 months, respectively.
- - Although abemaciclib was associated with some adverse events, they were manageable, and it demonstrated a trend toward overall survival (OS
Article Synopsis
- Some follicular lymphoma (FL) patients on a "watch and wait" strategy experience quick disease progression, prompting researchers to find ways to identify these individuals and develop a risk score for better screening at diagnosis.
- In a study involving 411 FL patients from 16 cancer centers, 35% required treatment within 24 months, with a significantly lower 5-year progression-free survival rate (62.3% vs. 89.5%) for those needing treatment early.
- Five key factors were identified as predictors for needing treatment within 24 months: advanced disease stages, high β microglobulin levels, low lymphocyte-to-monocyte ratios, bone marrow involvement, and spleen enlargement; these factors can help pinpoint patients who
Article Synopsis
- Recent studies emphasize the significance of fatty acid metabolism in cancer, particularly highlighting Sirtuin 3 (SIRT3) as a key regulator in this process for cancer cells.
- Research investigates the role of the long non-coding RNA TPTEP1 in triple-negative breast cancer (TNBC), which is found to be lowly expressed and down-regulated by the YY1 transcription factor.
- TPTEP1 acts as a tumor suppressor by inhibiting TNBC cell activities such as proliferation and invasion, and it regulates SIRT3 through a specific signaling pathway involving miR-1343-3p and Wnt/β-catenin.
Background: Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.
Methods: We conducted a phase 3, multicenter, open-label trial involving patients with hormone receptor-positive metastatic breast cancer with low HER2 expression (a score of 1+ or 2+ on immunohistochemical [IHC] analysis and negative results on in situ hybridization) or ultralow HER2 expression (IHC 0 with membrane staining) who had received one or more lines of endocrine-based therapy and no previous chemotherapy for metastatic breast cancer.
Disrupting the conserved multivalent binding of hemagglutinin (HA) on influenza A virus (IAV) to sialic acids (SAs) on the host cell membrane offers a robust strategy to block viral attachment and infection, irrespective of antigenic evolution or drug resistance. In this study, we exploit red blood cell-derived small extracellular vesicles (RBC sEVs) as nanodecoys by harnessing their high abundance of surface-displayed SAs to interact with IAV through multivalent HA-SA interactions. This high-avidity binding inhibits viral adhesion to the cell surface, effectively preventing both attachment and infection in a dose-dependent manner.
View Article and Find Full Text PDFArticle Synopsis
- F-627 (efbemalenograstim alfa) is a new long-acting G-CSF designed to reduce neutropenia in patients undergoing chemotherapy, and this study compared its efficacy and safety against the standard treatment, filgrastim.
- In a multicenter, randomized trial with 239 patients, participants received either a single injection of F-627 or daily injections of filgrastim after chemotherapy with epirubicin and cyclophosphamide, focusing on the duration of severe neutropenia as the primary endpoint.
- Results showed that both treatments had similar effects on the duration of severe neutropenia, with F-627 being well tolerated and possibly offering some advantages in terms of a lower incidence and shorter